Teva Pharmaceutical Industries and Lonza Group have decided to discontinue their biosimilars collaboration following a strategic review of the Teva-Lonza Joint Venture (TL-JV). The TL-JV began in 2009; the move will allow both companies to pursue their own strategies based on the investments and progress that the joint venture has made thus far.
Dr. Michael Hayden, president, Global R&D and chief scientific officer of Teva, said, “Teva has a track record of success in the biologics arena and we plan to continue and build on that success. This decision supports our ability to maintain a highly selective approach in our efforts to create a balanced portfolio of biosimilars, biobetters and innovative biologics that align with our overall portfolio and areas of disease focus, and by doing so better support our patients in these areas.”
Dr. Stephan Kutzer, chief operating officer of Lonza Pharma & Biotech Market Segment, said, “With the discontinuation of the joint venture we will cease investing in areas that are not strategic to Lonza such as clinical developments and end product commercialization. In our assessment those investments in biosimilars will require more capital than initially planned and will also take more time until they reach the market. This is why we intend in the future to limit our role by focusing on our core expertise in the areas of contract manufacturing and cell line development.”